308 related articles for article (PubMed ID: 2448656)
1. Biochemical and pharmacologic rationale for high-dose methotrexate.
Jolivet J
NCI Monogr; 1987; (5):61-5. PubMed ID: 2448656
[TBL] [Abstract][Full Text] [Related]
2. Biochemical factors in the selectivity of leucovorin rescue: selective inhibition of leucovorin reactivation of dihydrofolate reductase and leucovorin utilization in purine and pyrimidine biosynthesis by methotrexate and dihydrofolate polyglutamates.
Goldman ID; Matherly LH
NCI Monogr; 1987; (5):17-26. PubMed ID: 2448654
[TBL] [Abstract][Full Text] [Related]
3. Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells.
Rhee MS; Galivan J; Wright JE; Rosowsky A
Mol Pharmacol; 1994 Apr; 45(4):783-91. PubMed ID: 7514264
[TBL] [Abstract][Full Text] [Related]
4. Determinants of the sensitivity of human small-cell lung cancer cell lines to methotrexate.
Curt GA; Jolivet J; Carney DN; Bailey BD; Drake JC; Clendeninn NJ; Chabner BA
J Clin Invest; 1985 Oct; 76(4):1323-9. PubMed ID: 2414316
[TBL] [Abstract][Full Text] [Related]
5. Thymidylate synthase as a target for growth inhibition in methotrexate-sensitive and -resistant human head and neck cancer and leukemia cell lines.
McGuire JJ; Magee KJ; Russell CA; Canestrari JM
Oncol Res; 1997; 9(3):139-47. PubMed ID: 9220499
[TBL] [Abstract][Full Text] [Related]
6. Intrinsic resistance of cervical squamous cell carcinoma cell lines to methotrexate (MTX) as a result of decreased accumulation of intracellular MTX polyglutamates.
Barakat RR; Li WW; Lovelace C; Bertino JR
Gynecol Oncol; 1993 Oct; 51(1):54-60. PubMed ID: 7694891
[TBL] [Abstract][Full Text] [Related]
7. Patterns of cross-resistance to the antifolate drugs trimetrexate, metoprine, homofolate, and CB3717 in human lymphoma and osteosarcoma cells resistant to methotrexate.
Diddens H; Niethammer D; Jackson RC
Cancer Res; 1983 Nov; 43(11):5286-92. PubMed ID: 6225514
[TBL] [Abstract][Full Text] [Related]
8. Role of methotrexate polyglutamylation and cellular energy metabolism in inhibition of methotrexate binding to dihydrofolate reductase by 5-formyltetrahydrofolate in Ehrlich ascites tumor cells in vitro.
Matherly LH; Fry DW; Goldman ID
Cancer Res; 1983 Jun; 43(6):2694-9. PubMed ID: 6189586
[TBL] [Abstract][Full Text] [Related]
9. Biochemical and growth inhibitory effects of the erythro and threo isomers of gamma-fluoromethotrexate, a methotrexate analogue defective in polyglutamylation.
McGuire JJ; Graber M; Licato N; Vincenz C; Coward JK; Nimec Z; Galivan J
Cancer Res; 1989 Aug; 49(16):4517-25. PubMed ID: 2472880
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms of resistance to antifolates, a review.
Banerjee D; Ercikan-Abali E; Waltham M; Schnieders B; Hochhauser D; Li WW; Fan J; Gorlick R; Goker E; Bertino JR
Acta Biochim Pol; 1995; 42(4):457-64. PubMed ID: 8852336
[TBL] [Abstract][Full Text] [Related]
11. [Clinical pharmacology of anticancer agents [Part 5] Antimetabolites (2)].
Nakamura T; Ueda T; Uchida M
Gan To Kagaku Ryoho; 1992 Mar; 19(3):409-20. PubMed ID: 1543370
[TBL] [Abstract][Full Text] [Related]
12. Antifolate polyglutamylation and competitive drug displacement at dihydrofolate reductase as important elements in leucovorin rescue in L1210 cells.
Matherly LH; Barlowe CK; Goldman ID
Cancer Res; 1986 Feb; 46(2):588-93. PubMed ID: 2416428
[TBL] [Abstract][Full Text] [Related]
13. Intracellular pharmacokinetics of methotrexate polyglutamates in human breast cancer cells. Selective retention and less dissociable binding of 4-NH2-10-CH3-pteroylglutamate4 and 4-NH2-10-CH3-pteroylglutamate5 to dihydrofolate reductase.
Jolivet J; Chabner BA
J Clin Invest; 1983 Sep; 72(3):773-8. PubMed ID: 6193143
[TBL] [Abstract][Full Text] [Related]
14. Dihydrofolate reductase binding and cellular uptake of nonpolyglutamatable antifolates: correlates of cytotoxicity toward methotrexate-sensitive and -resistant human head and neck squamous carcinoma cells.
Chen G; Wright JE; Rosowsky A
Mol Pharmacol; 1995 Oct; 48(4):758-65. PubMed ID: 7476904
[TBL] [Abstract][Full Text] [Related]
15. Inherent resistance of human squamous carcinoma cell lines to methotrexate as a result of decreased polyglutamylation of this drug.
Pizzorno G; Chang YM; McGuire JJ; Bertino JR
Cancer Res; 1989 Oct; 49(19):5275-80. PubMed ID: 2475246
[TBL] [Abstract][Full Text] [Related]
16. The mechanism of transport of the multitargeted antifolate (MTA) and its cross-resistance pattern in cells with markedly impaired transport of methotrexate.
Zhao R; Babani S; Gao F; Liu L; Goldman ID
Clin Cancer Res; 2000 Sep; 6(9):3687-95. PubMed ID: 10999762
[TBL] [Abstract][Full Text] [Related]
17. High-dose methotrexate and/or leucovorin rescue for the treatment of children with lymphoblastic malignancies: do we really know why, when and how?
Sterba J; Valík D; Bajciová V; Kadlecová V; Gregorová V; Mendelová D
Neoplasma; 2005; 52(6):456-63. PubMed ID: 16284689
[TBL] [Abstract][Full Text] [Related]
18. Establishment of methotrexate-resistant human acute lymphoblastic leukemia cells in culture and effects of folate antagonists.
Ohnoshi T; Ohnuma T; Takahashi I; Scanlon K; Kamen BA; Holland JF
Cancer Res; 1982 May; 42(5):1655-60. PubMed ID: 6978176
[TBL] [Abstract][Full Text] [Related]
19. Methotrexate-leucovorin factor rescue regimens in diffuse large cell lymphoma.
Skarin AT; Canellos GP
NCI Monogr; 1987; (5):71-6. PubMed ID: 3501548
[TBL] [Abstract][Full Text] [Related]
20. [Primary study on establishment of namalwa 12/MTX resistant cell strain and its mechanism].
Chen J; Gu LJ; Ying DM; Shen M; Wu HJ
Ai Zheng; 2002 Dec; 21(12):1335-40. PubMed ID: 12520743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
